REFERENCES
- National Institute for Health and Care Excellence. Long-acting reversible contraception (CG30). Accessed 22 May 2013 from: http://www.nice.org.uk/CG030
- The American Congress of Obstetricians and Gynecologists. Long acting reversible contraception program. Accessed 22 May 2013 from: http://www.acog.org/About_ACOG/ACOG_Departments/Long_Acting_Reversible_Contraception
- Washington University. The contraceptive CHOICE project. Accessed 22 May 2013 from: http://www.choiceproject.wustl.edu/
- Family Planning NSW. Reproductive and sexual health in New South Wales and Australia: Differentials, trends and assessment of data sources. Ashfield, Sydney: FPNSW 2011.
- Secura GM, Allsworth JE, Madden T, et al. The contraceptive CHOICE project: Reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol 2010;203:115.e1–7.
- Haimovich S. Profile of long-acting reversible contraception users in Europe. Eur J Contracept Reprod Health Care 2009;14:187–95.
- Arribas-Mir L, Rueda-Lozano D, Agrela-Cardona M, et al. Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain. Contraception 2009;80:457–62.
- Weisberg E, Fraser I. Australian women's experience with Implanon. Aust Fam Physician 2005;34:694–6.
- Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon® users accessing two family planning clinics in Queensland, Australia. Contraception 2009;80:527–32.
- Lakha F, Glasier AF. Continuation rates of Implanon in the UK: Data from an observational study in a clinical setting. Contraception 2006;74:287–9.
- Agrawal A, Robinson C. An assessment of the first 3 years’ use of Implanon in Luton. J Fam Plann Reprod Health Care 2005;31:310–2.
- Dubuisson JB, Mugnier E, The Mirena Study Group. Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: Results of a French clinical study in women aged 35–45 years. Contraception 2002;66:121–8.
- Diaz J, Bahamondes L, Monteiro I, et al. Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil. Contraception 2000;62:59–61.
- Concin H, Bösch H, Hintermüller P, et al. Use of the levonorgestrel-releasing intrauterine system: An Austrian perspective. Curr Opin Obstet Gynecol 2009;21 (Suppl. 1): S1–9.
- Lei ZW, Wu SC, Garceau RJ, et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depomedroxyprogesterone acetate for contraception. Contraception 1996;53:357–61.
- Canto De Cetina TE, Cantoa P, Luna MO. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception 2001;63:143–6.
- Backman T, Huhtala S, Blom T, et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: A nation- wide study of 17,360 users. BJOG 2000;107: 335–9.
- French R, Van Vliet H, Cowan F, et al. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database Syst Rev 2004;(3):CD001776.